drugset / Trial / NCT04208698

A Scintigraphy Study in Adults With Diabetic Gastroparesis

NCT04208698 ↗

Phase 2 Terminated 2 enrolled CinDome Pharma, Inc.
RandomizedSequentialTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.

Timeline

Start
2020-02-17
Primary completion
2020-03-31
Completion
2020-03-31

Outcome

Outcome not reported

Stopped: “Trial was terminated due to the impact of COVID-19 on trial activities.”

Drugs

EvaluationDrugModalityDoseRoute
Subject CIN-102 Unknown — Oral

Indications